eligibility_summary
Eligible participants have relapsed/refractory multiple myeloma. Part A: ≥3 prior therapy lines, Parts B/C: 1–3 prior lines. Exclude anyone previously treated with alnuctamab or mezigdomide. Additional protocol-defined criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b/2a open-label study in relapsed/refractory multiple myeloma testing: (1) Alnuctamab (BMS-986349/CC-93269), a bispecific T-cell engager antibody targeting BCMA×CD3 that redirects CD3+ T cells to kill BCMA+ malignant plasma cells via immune synapse formation and cytokine-mediated cytotoxicity, (2) Mezigdomide (BMS-986348/CC-92480), a next-gen CELMoD (cereblon E3 ligase modulator/IMiD) that binds CRBN to degrade IKZF1/IKZF3, suppressing IRF4/MYC in myeloma cells and enhancing T/NK activation and IL-2, (3) Dexamethasone, a corticosteroid for anti-myeloma activity and toxicity mitigation. Targets/pathways: BCMA on plasma cells, CD3 on T cells, CRBN–ubiquitin-proteasome pathway, Ikaros/Aiolos–IRF4 axis, T/NK-cell activation. Arms include combo and alnuctamab alone.